Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

NCT07342283 is registered in ClinicalTrials.gov with Affiliated Hospital of Nantong University as lead sponsor.

NCT NCT07342283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07342283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Lead sponsor
Affiliated Hospital of Nantong University
Phase
Phase 2
Overall status
Recruiting
Start date
February 25, 2026
Completion date
December 25, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer (tnbc)